Creating the Artificial Womb

Marcus Davey, PhD

Disclosures

- No financial disclosures
- Patent holder on technology to be presented





A beginning, is a very delicate time



The lungs are the only major organ that have not performed their primary function before birth (Harding and Hooper)

Consequences of extreme prematurity (<28 wks)





Organ immaturity and iatrogenic injury

Nothing has changed over the past 15 years!

Consuming more medical resources (\$32B in 2017)




Babilmproved survivat of the EEBW infant has hot been associated with a parallel improvement in the major morbidities — in fact, with earlier limits of viability, there are more total patients with severe complications of prematurity than there were a decade ago.

March of Dimes - 2013

Extreme Prematurity – early mortality

(Patel et al., *NEJM*, 2015)




Organ immaturity and iatrogenic lung injury are responsible for the majority of deaths

Any form of mechanical ventilation is **NON PHYSIOLOGIC**




Mechanical ventilation, high FiO₂



Lung injury / arrested alveolar development

nCPAP, nIPPC, HHFNC, permissive hypercapnia AC/SIMV, VTV, HFJV, HFOV, synchronized NIPPV, non-Synchronized NIPPV, BiPAP, early iNO, Non-invasive iNO, steroids

No ventilation modality when studied by RCT has reduced death or BPD in <u>extreme</u> premature infants



We need better tools!



An artificial womb provides physiologic equipoise

- Maintain the extreme preterm infant in a fetal-like environment to allow <u>normal</u> ongoing growth and maturation
- Avoid negative consequences of invasive respiratory support


Membrane oxygenator

- "pumpless" circuit


Umbilical cannulation


- native cord

Fluidic environment -sealed /sterile



A NICU therapy to achieve a mortality and morbidity "time-shift"






- Initial target population : 23-25 weeks
- Incubation period 3-4 weeks → standard NICU care

History of the "Artificial Womb"

60 years of experimental effort





Obstacles

- Fetal heart extremely sensitive to pre-load or afterload imbalance
 high resistance oxygenators, pumped circuits
- Infection is a major hurdle for warm fluidic environments
- UA/UV access is challenging due to spasm, vascular integrity

Evolution of the Artificial Womb (2013 -15)


















- Sepsis drove new design
- Switch from recirculation to circulation of synthetic amniotic fluid
- Duration of studies progressed from days to weeks


The CHOP Biobag


- Open sided design, adjustable size
- Adjustable number, size, and configuration of ports
- Silver impregnated polyethylene film
- Once sealed, completely closed system, efficiencies of flow and volume
- Translucent and sonolucent



Location, location, location







Cannulation site

Blood Flow (%norm)

O₂ delivery (%norm)

Flow interruptions /day

Problems

Carotid-Jugular

45 %

30 %

89

Hydrops

↑RH press.

Carotid - UV

80 %

75%

41

↑risk of decannulation

UA(x2) - UV


100 %

100%

2

Umbilical cannulation of preterm lambs

EXTrauterine Environment for Neonatal Development- EXTEND




Umbilical interface




- up to 4 weeks of physiologic support
- continuous AF circulation
- no sedation allows FBM's & swallowing
- normal CCO, O₂ delivery/consumption, CBF

Maintenance of the Fetal Circulation

Ductus Arteriosus







Maintenance of the Fetal Circulation

Ductus Venosus






Foramen Ovale







Contrast-enhanced ultrasound



Somatic Growth and Maturation




Sheep TPN Lipids



107 Days of gestation


132 Days of gestation

Real-time patient monitoring



- Real-time O₂ delivery
- Oxygenator efficiency index

Lung development / respiratory function







3-4 weeks of therapy

	Published Control (n=11)§	UA/UV (n=5)	Near-term Control‡ (n=3)
GA (days)	128	136±2	141±1
P _a CO ₂ (mm Hg)	63±5	35±4	35±1
Resp Rate (bpm)	40	39±4	43±3
PIP (cm H ₂ O)	36±1	17±1	21±1
PEEP (cm H ₂ O)	3	5.5±0.2	5±0
pН	7.15±0.04	7.36±0.02	7.45±0.02
P _a O ₂ (mm Hg)	197±29	128±12	143±24
f _i O ₂ (%)	100	33±1	32±2
PIP (cm H ₂ O)	36±1	18±2	22±1
PEEP (cm H ₂ O)	3	5.7±0.2	5±0
A-a gr (mm Hg)	437	59±11	38±11

Life beyond EXTEND


Normal neurological function & development









Size equivalence 24 wks (0.5 kg)



Screening clinical prototypes





Human cord @ 22wks



Prototyping membrane oxygenators

- blood transit times
- Priming volume
- gas exchange capacity





From Barn to Beside:

the path to clinical translation



Device design concept



Mobile

Sweep gases

Amniotic Fluid Bags

Ultrasound

Camera





A paradigm shift in neonatal care


Current NICU Care

Intubation / suctioning
mechanical ventilation with high FiO₂
repositioning → head molding
skin assessment
diaper change, bathing, oral care
External noise / light
Oral care


EXTEND

n/a
n/a; biopod rotation Q12
n/a; BW ~10% submerged
n/a
none to minimal
n/a






Regulatory Roadmap





Regulatory / FDA Compliance / Animal Testing Partner

Preclinical animal study at CHOP



Initiated: Feb 2018 (18-24 months duration)

"Wins" with the FDA
GLP-like
No long-term neurological follow-up

The Key to success



The "LICU"



Children's Hospital of Philadelphia

BREAKTHROUGHS.

EVERY DAY.

